At USAntibiotics, the only remaining US manufacturer of Amoxicillin, we are committed to providing a stable supply of antibiotics to healthcare providers and patients across the country. We have expressed deep concern about the offshoring of pharmaceutical production, and continue to encourage the White House and HHS to rectify this issue.
I urge the government to seek assistance in combating this problem domestically. Reliance on foreign manufacturers puts our nation at risk and Americans’ lives in danger.
Our 360,000-square-foot facility in Bristol, Tennessee, can produce and store every dose of Amoxicillin needed in the U.S. for the next five years. We stand ready to help solve today’s problems and prevent dangerous shortages in the future.
Editor’s note: This letter to the editor is in response to the following article Becker’s published March 8: Amoxicillin shortage continues as resupply dates are delayed again.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.